← back to search

Saul N. Faust

University of Nottingham · GB
Area of research
Epidemiology · Infectious Diseases
Research interest
Research interests include Pneumonia and Respiratory Infections, SARS-CoV-2 and COVID-19 Research, Bacterial Infections and Vaccines, and Respiratory viral infections research.
h-index
74
citations
39,549
works
426
NIH funding
primary concept
Medicine
email

Recent publications

Enablers and barriers to participation in vaccine trials: a narrative synthesis.
2026cited by 0position: contributordoi
Evaluating antibiotic medications delivered through elastomeric devices in a paediatric population: a systematic review.
2026cited by 0position: contributordoi
Safety, colonisation kinetics, transmissibility, and immune correlates of protection in healthy adults inoculated with Bordetella pertussis in England: a single-centre, open-label, phase 1, controlled human infection study.
2026cited by 0position: contributordoi
MR-Pro-adrenomedullin (MR-proADM) and Host Immune Response Biomarkers Evaluation of procalcitonin-guided antibiotic duration in Children with Infection for Stratification of Effectiveness: the PRECISE Study
2026cited by 0position: contributor
Controlled Human Infection of Healthy Adults With Lyophilized <i>Neisseria lactamica</i> Induces Asymptomatic, Immunogenic Nasopharyngeal Carriage in the United Kingdom and Mali.
2026cited by 0position: contributordoi
Safety, tolerability and immunogenicity of SPVX02, a room temperature-stabilised Tetanus-Diphtheria vaccine compared to Tetadif and diTeBooster: a multicentre, phase 1, blinded, randomised clinical trial
2026cited by 0position: contributordoi
Quality of life of X-linked agammaglobulinemia patients in the United Kingdom
Journal of Human Immunity 2026cited by 0position: contributordoi
MR-Pro-adrenomedullin (MR-proADM) and Host Immune Response Biomarkers Evaluation of procalcitonin-guided antibiotic duration in Children with Infection for Stratification of Effectiveness: the PRECISE Study
Efficacy and Mechanism Evaluation 2026cited by 0position: contributordoi
A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus Vaccine
Journal of Infection 2026cited by 0position: contributordoi
180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial.
2025cited by 27position: contributordoi
Procalcitonin-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection in the UK (BATCH): a pragmatic, multicentre, open-label, two-arm, individually randomised, controlled trial
The Lancet Child & Adolescent Health 2025cited by 13position: middledoi
Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial.
2025cited by 12position: contributordoi
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.
2025cited by 9position: contributordoi
Procalcitonin-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection in the UK (BATCH): a pragmatic, multicentre, open-label, two-arm, individually randomised, controlled trial.
2025cited by 5position: contributordoi
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
2025cited by 5position: contributordoi
Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis.
2025cited by 4position: contributordoi
Identification and antimicrobial resistance profiling of Pseudomonas aeruginosa using multi-excitation Raman spectroscopy and computational analytics.
2025cited by 2position: contributordoi
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
2025cited by 2position: contributordoi
Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST).
2025cited by 1position: contributordoi
Requirements and special considerations for drug trials with children across six jurisdictions: 2. Ethics review in the regulatory approval process.
2025cited by 1position: contributordoi
Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A Vaccine.
2025cited by 1position: contributordoi
Development of a multicentre cohort study to understand the role of MRI and ultrasound in the diagnosis of acute haematogenous bone and joint infection in children (the PIC Bone study) : a study protocol.
2025cited by 1position: contributordoi
Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT.
2025cited by 1position: contributordoi
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study
Journal of Infection 2025cited by 0position: contributordoi
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial.
2025cited by 0position: contributordoi
Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)
2025cited by 0position: contributordoi
Long-term follow-up of treatment comparisons in RECOVERY: a randomised, open-label, platform trial for patients hospitalised with COVID-19
2025cited by 0position: contributordoi
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
The Lancet Child & Adolescent Health 2024cited by 35position: firstdoi
Oral Valganciclovir Initiated Beyond 1 Month of Age as Treatment of Sensorineural Hearing Loss Caused by Congenital Cytomegalovirus Infection: A Randomized Clinical Trial
The Journal of Pediatrics 2024cited by 32position: middledoi
Oral Valganciclovir Initiated Beyond 1 Month of Age as Treatment of Sensorineural Hearing Loss Caused by Congenital Cytomegalovirus Infection: A Randomized Clinical Trial.
2024cited by 20position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 30 papers (2019–2026)Christopher A Green · Johns Hopkins Hospital23 papers (2020–2024)Robert C. Read · Churchill Hospital19 papers (2019–2026)Paul T. Heath · NIHR Southampton Biomedical Research Centre19 papers (2020–2023)Anna L Goodman · St. Thomas Hospital18 papers (2021–2023)Angela M. Minassian · National Institute for Health Research16 papers (2021–2023)Enitan D. Carrol · University of Liverpool14 papers (2020–2026)Emma C. Thomson · MRC University of Glasgow Centre for Virus Research13 papers (2021–2023)Luregn J. Schlapbach · The University of Queensland13 papers (2020–2024)Tommy Rampling · University College London Hospitals NHS Foundation Trust13 papers (2021–2024)Adam Finn · University of Bristol13 papers (2019–2022)Thomas C. Darton · University of Sheffield12 papers (2021–2025)Christopher J.A. Duncan · National Institute of Environmental Health Sciences11 papers (2021–2023)Elizabeth Clutterbuck · University of Oxford10 papers (2021–2023)Christine E. Jones · University of Surrey10 papers (2020–2024)R. H. Shaw · University of Oxford10 papers (2021–2023)Simon B. Drysdale · St George’s University Hospitals NHS Foundation Trust9 papers (2020–2025)Michael J. Kelso · The University of Texas Southwestern Medical Center9 papers (2012–2020)Patrick Lillie · Castle Hill Hospital8 papers (2021–2025)Federico Martinón-Torres · Hospital General Universitario Gregorio Marañón8 papers (2019–2023)